比较IN-REC-SUR-E与LISA在呼吸窘迫综合征早产儿中的应用:一项随机对照试验(IN-REC-LISA试验)
本研究为国际、非盲、多中心随机对照试验,拟纳入382例胎龄24+0至27+6周、产房未插管且生后24小时内无创通气失败的早产儿,1:1随机接受IN-REC-SUR-E或LISA技术给予肺表面活性物质,主要结局为36周矫正胎龄时无支气管肺发育不良(BPD)生存的复合结局。
要点
- 拟纳入382例胎龄24+0至27+6周、生后24小时内nCPAP或NIPPV失败的早产儿,1:1随机分组。
- 主要结局为36周矫正胎龄时死亡或BPD的复合结局。
- 采用意向性分析和符合方案分析,以log-binomial回归模型估计校正相对风险(RR)。
核心结论
- 该试验旨在比较IN-REC-SUR-E与LISA两种肺表面活性物质给药方法在提高胎龄24+0至27+6周呼吸窘迫综合征早产儿36周矫正胎龄时无BPD生存方面的效果。
研究设计与样本
- 国际、非盲、多中心随机对照试验,拟纳入382例胎龄24+0至27+6周、产房未插管且生后24小时内nCPAP或NIPPV失败的早产儿,1:1随机接受IN-REC-SUR-E或LISA给药;随机化采用中心化分层区组设计,分层因素为中心和胎龄(24+0至25+6周或26+0至27+6周)。
主要发现
- 原文未报告本研究的结果数据。
关键数值与推荐
- 主要结局为36周矫正胎龄时死亡或BPD的复合结局;次要结局包括36周矫正胎龄时BPD、死亡、脉搏血氧饱和度/吸入氧浓度、严重脑室内出血、气胸、呼吸支持和氧疗持续时间、肺出血、接受治疗的动脉导管未闭、接受更多剂次肺表面活性物质的婴儿百分比、脑室周围白质软化、严重早产儿视网膜病变、坏死性小肠结肠炎、脓毒症、总住院时间、全身性产后激素使用、24月龄时神经发育结局和呼吸功能检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surfactant is a well-established therapy for preterm neonates affected by respiratory distress syndrome (RDS). The goals of different methods of surfactant administration are to reduce the duration of mechanical ventilation and the severity of bronchopulmonary dysplasia (BPD); however, the optimal administration method remains unknown. This study compares the effectiveness of the INtubate-RECruit-SURfactant-Extubate (IN-REC-SUR-E) technique with the less-invasive surfactant administration (LISA) technique, in increasing BPD-free survival of preterm infants. This is an international unblinded multicenter randomized controlled study in which preterm infants will be randomized into two groups to receive IN-REC-SUR-E or LISA surfactant administration. METHODS: In this study, 382 infants born at 24+0-27+6 weeks' gestation, not intubated in the delivery room and failing nasal continuous positive airway pressure (nCPAP) or nasal intermittent positive pressure ventilation (NIPPV) during the first 24 h of life, will be randomized 1:1 to receive IN-REC-SUR-E or LISA surfactant administration. The primary outcome is a composite outcome of death or BPD at 36 weeks' postmenstrual age. The secondary outcomes are BPD at 36 weeks' postmenstrual age; death; pulse oximetry/fraction of inspired oxygen; severe intraventricular hemorrhage; pneumothorax; duration of respiratory support and oxygen therapy; pulmonary hemorrhage; patent ductus arteriosus undergoing treatment; percentage of infants receiving more doses of surfactant; periventricular leukomalacia, severe retinopathy of prematurity, necrotizing enterocolitis, sepsis; total in-hospital stay; systemic postnatal steroids; neurodevelopmental outcomes; and respiratory function testing at 24 months of age. Randomization will be centrally provided using both stratification and permuted blocks with random block sizes and block order. Stratification factors will include center and gestational age (24+0 to 25+6 weeks or 26+0 to 27+6 weeks). Analyses will be conducted in both intention-to-treat and per-protocol populations, utilizing a log-binomial regression model that corrects for stratification factors to estimate the adjusted relative risk (RR). DISCUSSION: This trial is designed to provide robust data on the best method of surfactant administration in spontaneously breathing preterm infants born at 24+0-27+6 weeks' gestation affected by RDS and failing nCPAP or NIPPV during the first 24 h of life, comparing IN-REC-SUR-E to LISA technique, in increasing BPD-free survival at 36 weeks' postmenstrual age of life. TRIAL REGISTRATION: ClinicalTrials.gov NCT05711966. Registered on February 3, 2023.
引用
- Vento G, Paladini A, Aurilia C, et al. Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial). Trials. 2024. PMID: 38956676. doi:10.1186/s13063-024-08240-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。